

Development of a gene therapy for ovarian cancer using bispecific shRNA and antibody escaping oncolytic adenovirus.

Curigin Co., Ltd.



ONCOLOGY	Lead
Product Type	Gene Therapy (siRNA)
Indication	Ovarian Cancer
Target	cMyc/BCL2
MoA(Mechanism of Action)	CA106T is an oncolytic adenovirus expressing bispecific shRNA targeting cMYC and BCL2 mRNAs.
Competitiveness	<ul style="list-style-type: none"> • Strong anti-cancer efficiency in ovarian cancer • RNAi directly targeting mRNAs of oncogenes, cMYC and BCL2 • shRNA efficiently processed in ovarian cancer • Specifically infects and proliferates in cancer cells • Modified capsid to avoid immunosurveillance
Development Stage	LEAD
Route of Administration	Intraperitoneal injection or Intravenous injection